Evidence map›Paper›PMID 39069541›Full record

ArticleMolecular diversity2025

Identification of the potential Pan-CDK antagonists: tracing the path of virtual screening and inhibitory activity on lung cancer cells.

Jia-Hao Tao, Ping-Lang Ruan, Jun Zhang, Yong Zhou, Cha-Xiang Guan

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Molegro Data Modeller to Estimate CDK6 Inhibition.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jia-Hao TaoDepartment of Physiology, School of Basic Medical Science, Central South University, Changsha, 410078, Hunan, China.
Ping-Lang RuanDepartment of Dermatology, Second Xiangya Hospital, Central South University, Hunan Key Laboratory of Medical Epigenomics, Changsha, 410078, Hunan, China.
Jun ZhangAscle Therapeutics, Suzhou, 215000, Jiangsu, China.
Yong ZhouDepartment of Physiology, School of Basic Medical Science, Central South University, Changsha, 410078, Hunan, China. zhouyong421@csu.edu.cn.
Cha-Xiang GuanDepartment of Physiology, School of Basic Medical Science, Central South University, Changsha, 410078, Hunan, China. guanchaxiang@csu.edu.cn.

Funding

Fundamental Research Funds for Central Universities of the Central South University 2020zzts772Hunan Provincial Innovation Foundation for Postgraduate CX20220321National Natural Science Foundation of China 82241053Postgraduate Innovative Project of Central South University 2021XQLX51
6 · The paper itself

Abstract

Cyclin-dependent kinases (CDKs) are overexpressed in tumor cells, and their aberrant activation can promote the progression of non-small-cell lung cancer (NSCLC). We utilized structure-based virtual screening and experimental validation to screen for potential CDKs antagonists among TargetMol natural products. Molecular docking and molecular dynamics simulation results indicate that Dolastatin 10 exhibits strong interactions with multiple subtypes of CDKs (CDK1, CDK2, CDK3, CDK4, and CDK6), forming stable CDKs-Dolastatin 10 complex compounds. Furthermore, in vitro experiments demonstrate that Dolastatin 10 significantly inhibits the viability, migration, and invasion of H1299 cells in a concentration-dependent manner, arresting the cell cycle at the G2/M phase by inducing cell senescence. These findings suggest that Dolastatin 10 may serve as a potential CDKs antagonist deserving further investigation.

Indexed as

Antineoplastic AgentsCyclin-Dependent KinasesLung NeoplasmsProtein Kinase InhibitorsCarcinoma, Non-Small-Cell LungCell Line, TumorCell MovementCell ProliferationCell SurvivalDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular Dynamics SimulationAntineoplastic AgentsCyclin-Dependent KinasesProtein Kinase InhibitorsCyclin-dependent kinase inhibitorDolastatin 10Molecular dockingMolecular dynamics simulationNon-small-cell lung cancer

Identifiers

PMID39069541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.